| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
AUDA is a novel and potent soluble epoxide hydrolase (sEH) inhibitor with anti-inflammatory activity. It exhibts IC50s of 18 and 69 nM for the mouse and human sEH, respectively.
| ln Vitro |
Rat VSMCs exposed to PDGF are inhibited in their proliferation in a dose-dependent manner by AUDA (0.3-10 μg/mL; 48 hours) [2]. COX-2 expression is dose-dependently upregulated by AUDA (0.3–10 μg/mL; 30 minutes) [2]. HCAEC's ability to migrate is improved by AUDA (10, 50, and 100 μM) in a dose-dependent way [3]. The capacity of HCAECs to adhere is greatly enhanced by AUDA [3].
|
|---|---|
| ln Vivo |
AUDA (ip; 10 mg/kg; 14 days) lowers the expression levels of IL-1β, MMP-9, and TNF-α [3].
|
| Cell Assay |
Cell proliferation assay [2]
Cell Types: Vascular smooth muscle cells (VSMC) Tested Concentrations: 0.3, 1, 3, 10 μg/mL Incubation Duration: 48 hrs (hours) Experimental Results: The proliferation of rat VSMCs exposed to PDGF was dose-dependently inhibited. Western Blot Analysis[2] Cell Types: VSMC Tested Concentrations: 1, 3, 10, 30 μg/mL Incubation Duration: 30 minutes Experimental Results: COX-2 expression was up-regulated in a dose-dependent manner. |
| Animal Protocol |
Animal/Disease Models: Male (wild-type) C57BL/6 mice (age, 4-6 weeks; body weight, 18-20 g) [3]
Doses: 10 mg/kg Route of Administration: intraperitoneal (ip) injection; 14-day Experimental Results: TNF -α, MMP-9 and IL-1β expression levels were diminished. |
| References |
|
| Additional Infomation |
AUDA is a medium-chain fatty acid.
|
| Molecular Formula |
C23H40N2O3
|
|---|---|
| Molecular Weight |
392.575306892395
|
| Exact Mass |
392.303
|
| CAS # |
479413-70-2
|
| PubChem CID |
10069117
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
592.7±19.0 °C at 760 mmHg
|
| Flash Point |
312.3±21.5 °C
|
| Vapour Pressure |
0.0±3.6 mmHg at 25°C
|
| Index of Refraction |
1.534
|
| LogP |
5.61
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
28
|
| Complexity |
479
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XLGSEOAVLVTJDH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H40N2O3/c26-21(27)10-8-6-4-2-1-3-5-7-9-11-24-22(28)25-23-15-18-12-19(16-23)14-20(13-18)17-23/h18-20H,1-17H2,(H,26,27)(H2,24,25,28)
|
| Chemical Name |
12-(1-adamantylcarbamoylamino)dodecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~318.41 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (5.30 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.30 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5473 mL | 12.7363 mL | 25.4725 mL | |
| 5 mM | 0.5095 mL | 2.5473 mL | 5.0945 mL | |
| 10 mM | 0.2547 mL | 1.2736 mL | 2.5473 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
